M. Marc Ohresser

Tél

0247366377

Mail

marc.ohresser@univ-tours.fr

Ohresser,M., P. Borsa, and C. Delsert. 1997. Intron-length polymorphism at theactin gene locus mac-1 : a genetic marker for population studiesin the marine mussels MytilusgalloprovincialisLmk. and M.edulisL..Molec Mar Biol Biotech 6 :123 30.

Volkoff, A.-N., P. Cérutti, J. Rocher, M.C.P. Ohresser,G. Devauchelle and M. Duonor-Cérutti. 1999. Related RNAs inlepidopteran cells after invitroinfection with HyposoterdidymatorVirus define a new polydnavirus gene family. Virology263:349-63.

Vonau, V., M. Ohresser,N. Bierne, C. Delsert, I. Beuzart, E. Bedier and F. Bonhomme. 1999.Three polymorphic microsatellites in the shrimp Penaeusstylirostris.Anim Genet30:234-5.

Loppes, R., M. Radoux, M.C. Ohresserand R.F. Matagne. 1999. Transcriptional regulation of the Nia1 geneencoding nitrate reductase in Chlamydomonasreinhardtii:effects of various environmental factors on the expression of areporter gene under the control of the Nia1 promoter. PlantMolecular Biology41:701-11.

Huvet, A., P. Boudry, M. Ohresser,C. Delsert and F. Bonhomme. 2000. Variable microsatellites in thePacific oyster Crassostreagigasand other cupped oyster species. An Genet 31 :71-2.

Cancela, M.L., M.C.P. Ohresser,J.P. Reia, M.K. Williamson and P.A. Price. 2001. Matrix Gla Proteinin Xenopuslaevis :molecular cloning, tissue distribution and evolutionaryconsiderations. J Bone Miner Res16 1611-21.

Volkoff, A.N., J. Rocher, P. Cerutti, M.C. Ohresser,Y. d'Aubenton-Carafa, G. Devauchelle and M. Duonor-Cerutti. 2001.Persistent expression of a newly characterized Hyposoterdidymatorpolydnavirus gene in long-term infected lepidopteran cell lines.J Gen Virol 82:963-9.

Pinto J.P., M.C. Ohresser,and M.L.Cancela 2001. Cloning of the bone Gla protein gene from theteleost fish Sparusaurata.Evidence for overall conservation in gene organization andbone-specific expression from fish to man. Gene270:77-91.

Conceição N., N.M. Henriques., M.C.P. Ohresser,P. Hublitz, R. Schüle and M.L. Cancela. 2002 Molecular cloning ofthe Matrix Gla Protein Gene from Xenopuslaevis.Functional analysis of the promoter identifies a calcium sensitiveregion required for basal activity. Eur J Bioch 269 :1-10.

TernantD., M. Ohresser,C. Thomas, G. Cartron, H. Watier, and G Paintaud. 2005Dose-response relationship and pharmacogenetics of anti-RhDmonoclonal antibodies. Blood106:1503-4.

WillotS., S. Vermeire, M. Ohresser,P. Rutgeerts, G. Paintaud, J. Belaiche, M. De Vos, A. Van Gossum, D.Franchimont, JF. Colombel,H. Watier, and E. Louis. 2006. No association between C-reactiveprotein gene polymorphisms and clinical or biological response toinfliximab in Crohn's disease. Pharmacogenet Genom16 :37-42.

DommangeF., G. Cartron, C. Espanel, J. Domenech, L. Benboubker, G. Gallay, M.Ohresser,P. Colombat, C. Binet, H. Watier, and O. Herault 2006. CXCL12polymorphismand malignant cell dissemination / tissue infiltration in acutemyeloid leukemia. FASEB J 20:1913-5.

P17(23,4)- OhresserM., D. Olive, B. Vanhove, and H. Watier. 2006 ; Comment on:« Risk in drug trials ». Lancet.368:2205-6.

Loisel S., M. Ohresser,M. Pallardy, D. Dayde, C. Berthou, G Cartron, and H Watier. 2007.Relevance, advantages and limitations of animal models used in thedevelopment of monoclonal antibodies for cancer treatment. Crit Rev  Oncol Hemato .62:34-42.

Magdelaine-Beuzelin C., Q. Kaas, V. Wehbi, M. Ohresser,R. Jefferis, M.-P. Lefranc, and H. Watier. 2007. Structure-functionrelationships of the variable domains of monoclonal antibodiesapproved for cancer treatment. Crit Rev  Oncol Hemato.64:210-225.

Ternant D., M. Buchler, M. Beneton, G. Alvan, M. Ohresser,G. Touchard, B. Hurault de Ligny, O. Toupance, H. Watier, Y.Lebranchu, and G. Paintaud. 2008. Interindividual variability in theconcentration-effect relationship of antilymphocyte globulins-apossible influence of FcRIIIagenetic polymorphism. Brit J Clin  Pharmacol .65:60-8.

Cartron G., M. Ohresser,G. Salles, P. Solal-Céligny, P.Colombatand H. Watier. 2008.Neutrophilrole in in vivo anti-lymphoma activity of rituximab:FCGR3B-NA1/NA2 polymorphism does not influence response andsurvival after rituximab treatment. An  Oncol .;19:1485-7.

Congy-Jolivet N., A. Bolzec, D. Ternant, M. Ohresser,H. Watier, and G. Thibault. 2008. FcgammaRIIIa expression is notincreased on natural killer cells expressing the FcgammaRIIIa-158Vallotype. Can Res .68:976-80.

Lejeune J., G. Thibault, D. Ternant, G.Cartron, H. Watier, and M. Ohresser.2008. Evidencefor Linkage Disequilibrium Between FcRIIIa-V158Fand FcRIIa-H131RPolymorphisms in White Patients, and for an Fc_RIIIa-Restricted Influence on the Responseto Therapeutic Antibodies Revisitingassociation studies between FcRpolymorphisms and clinical responses to therapeutic antibodies.J  Clin  Oncol .26:5489-91.

DaydéD.,D. Ternant, M. Ohresser,S. Lerondel, S. Pesnel, H. Watier, A. Le Pape, P. Bardos, G.Paintaud, and G. Cartron. 2009. Tumorburden influences exposure and response to rituximab: pharmacokinetic- pharmacodynamic modelling using a syngeneic bioluminescent murinemodel expressing human CD20. Blood.113:3765-72.

Magdelaine-Beuzelin C., S. Vermeire,M. Goodall, F. Baert, G. Van Assche, M. Ohresser,D. Degenne, J. M. Dugoujon, R. Jefferis, P. Rutgeerts, M.-P. Lefranc,and H. Watier. 2009.G1mallotypes and development of antibodies-to-infliximab.Pharmacogenet  and Genom .19:383-7.

Bruyère F., C. M. Hovens, M.-N. Marson, B. Faivre d'Arcier,A. J. Costello, H. Watier, C. Linassier, and M. Ohresser.2010.VEGFpolymorphisms are associated with an increasing risk of developingRenal Cell Carcinoma.J  Urol .in press.